U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C18H21NO3.H2O.2H3O4P
Molecular Weight 812.7341
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CODEINE PHOSPHATE

SMILES

O.OP(O)(O)=O.OP(O)(O)=O.COC1=C2O[C@H]3[C@@H](O)C=C[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C.COC6=C7O[C@H]8[C@@H](O)C=C[C@H]9[C@H]%10CC(C=C6)=C7[C@@]89CCN%10C

InChI

InChIKey=DKSZLDSPXIWGFO-BLOJGBSASA-N
InChI=1S/2C18H21NO3.2H3O4P.H2O/c2*1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;2*1-5(2,3)4;/h2*3-6,11-13,17,20H,7-9H2,1-2H3;2*(H3,1,2,3,4);1H2/t2*11-,12+,13-,17-,18-;;;/m00.../s1

HIDE SMILES / InChI
Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C18H21NO3
Molecular Weight 299.3642
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.

CNS Activity

Approval Year

1921
1468
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2752
 6.1 µM [EC50]
Kappa-type opioid receptor
61
Target ID: P41145
Gene ID: 4986.0
Gene Symbol: OPRK1
Target Organism: Homo sapiens (Human)
Agonist
2752
Delta-type opioid receptor
46
Target ID: P41143
Gene ID: 4985.0
Gene Symbol: OPRD1
Target Organism: Homo sapiens (Human)
Agonist
2752
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CAPITAL AND CODEINE

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
66.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
145 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
229 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
93 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
242 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
53.5 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MORPHINE-3-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
66.9 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
968 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE-6-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.61 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
466 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
849 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
467 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
937 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.47 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.7 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, oral
dose: 60 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/7094509/
60 mg single, intramuscular
dose: 60 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.71 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MORPHINE-3-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1.47 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2.75 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/1391681/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE-6-GLUCURONIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
75%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CODEINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
360 mg 1 times / day multiple, oral
Highest recorded dose
Dose: 360 mg, 1 times / day
Route: oral
Route: multiple
Dose: 360 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
unhealthy
Health Status: unhealthy
Sex: M+F
Food Status: UNKNOWN
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252
inhibitor
2438
substrate
1388

inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OCT1
620

UGT2B7
197

CYP19A1
429

CYP1A2
2153
UGT2B7
456

UGT1A3
470

UGT1A1
479

UGT1A4
399

OCT1
393

UGT2B4
278

UGT1A8
323

UGT1A10
331

P-gp
2052

UGT2B15
236
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
2546
 inconclusive [IC50 35.7774 uM]
CYP19A1
430
 no
CYP1A2
2333
 no
CYP2C9
2497
 no
CYP3A4
2633
 no
UGT2B7
210
 unlikely [IC50 400 uM]
OCT1
656
 yes [IC50 10.5 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT2B4
278
 major
UGT2B7
456
 major
P-gp
2052
 no
UGT1A10
331
 no
UGT1A3
470
 no
UGT1A4
399
 no
UGT1A8
323
 no
UGT2B15
236
 no
CYP2D6
1388
 yes
CYP3A4
1946
 yes
OCT1
393
 yes
UGT1A1
479
 yes
Morphine
12
UGT2B7
456
 yes
Morphine
12
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1Q4DTD
Alfa Chemistry
170301
Alfa Chemistry
ACM52453040
AN PharmaTech
AN-23899
Angene
AGN-PC-0U9ZUU
Aurora Fine Chemicals LLC
A17.876.233
http://online.aurorafinechemicals.com/info?ID=A17.876.233
Avantor Inc
75835-236
https://us.vwr.com/store/product/21998648/exempted-drug-of-abuse-reference-standards-restek
Changzhou Highassay Chemical Co., Ltd
my_sub1415
Chemieliva Pharmaceutical Co., Ltd
PBCM0821173
ChemMol
30101025
http://www.chemmol.com/chemmol/30101025.html
ChemMol
49416695
http://www.chemmol.com/chemmol/49416695.html
ChemMol
99138769
http://www.chemmol.com/chemmol/99138769.html
Clearsynth
CS-T-56966
http://www.clearsynth.com/en/CST56966.html
Compound Cloud
21155870
Compound Cloud
24892867
Compound Cloud
5284371
Compound Cloud
5362471
Compound Cloud
6321303
eMolecules
193733897
Hangzhou APIChem Technology
AC-11114
HongKong Chemhere
SCA54117
IBScreen
BB_NC-00138
IBScreen
STOCK1N-42851
LGC Standards
LGCAMP0004.10-01
https://www.lgcstandards.com/US/en/p/LGCAMP0004.10-01
LGC Standards
LGCAMP0004.10-02
https://www.lgcstandards.com/US/en/p/LGCAMP0004.10-02
LGC Standards
LGCFOR0004.10
https://www.lgcstandards.com/US/en/p/LGCFOR0004.10
LGC Standards
MM0004.10
https://www.lgcstandards.com/US/en/p/MM0004.10
mcule
MCULE-4129237460
mcule
MCULE-6243921692
Parchem
87121
https://www.parchem.com/chemical-supplier-distributor/Codeine-Alkaloid-087121.aspx
Parchem
87123
https://www.parchem.com/chemical-supplier-distributor/Codeine-USP-087123.aspx
Sigma-Aldrich
C-006_CERILLIAN
https://www.sigmaaldrich.com/catalog/product/cerillian/c006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
C1653_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/c1653?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
Y0000722_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/y0000722?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma Aldrich
C1653|SIAL
Sigma Aldrich
C3539|SIAL
Sigma Aldrich
C5901|SIAL
Sigma Aldrich
Y0000722
Sigma Aldrich
Y0000722|SIAL
Smolecule
S627560
https://www.smolecule.com/products/s627560
Tetrahedron
TS63993
Tetrahedron
TS80953
Toronto Research Chemicals
C634075
Toronto Research Chemicals
C634080
Toronto Research Chemicals
KIT0410
Toronto Research Chemicals
KIT2460
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.
PH-1498A
ZINC
ZINC000003806721
http://zinc15.docking.org/substances/ZINC000003806721
PubMed

PubMed

TitleDatePubMed
Mimicking gene defects to treat drug dependence.
2000
Over-the-counter medications for acute cough in children and adults in ambulatory settings.
2001
LC method for the analysis of acetylsalicylic acid, caffeine and codeine phosphate in pharmaceutical preparations.
2001 Apr
The diagnosis and treatment of cough.
2001 Apr 5
LC method for the analysis of paracetamol, caffeine and codeine phosphate in pharmaceutical preparations.
2001 Dec
Effect of penicillin on postoperative endodontic pain and swelling in symptomatic necrotic teeth.
2001 Feb
Effect of prophylactic amoxicillin on endodontic flare-up in asymptomatic, necrotic teeth.
2001 Jan
Inhibition by glucocorticoids of the mast cell-dependent weal and flare response in human skin in vivo.
2001 Jan
Packaging of codeine phosphate suppositories.
2001 Jan
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.
2001 Jan 10
Head-column field-amplified sample stacking in presence of siphoning. Application to capillary electrophoresis-electrospray ionization mass spectrometry of opioids in urine.
2001 Jul 27
[Information on preparations containing codeine].
2001 Jun 20
Myocardial Infarction associated with methadone and/or dihydrocodeine.
2001 Mar
Opiate use to control bowel motility may induce chronic daily headache in patients with migraine.
2001 Mar
Audit of pain management at home following tonsillectomy in children.
2001 Mar
Treatment of severe pain from osteoarthritis with slow-release tramadol or dihydrocodeine in combination with NSAID's: a randomised study comparing analgesia, antinociception and gastrointestinal effects.
2001 Mar
Dextromethorphan is an effective cough suppressant.
2001 May
Capillary electrophoresis-electrospray ionization ion trap mass spectrometry for analysis and confirmation testing of morphine and related compounds in urine.
2001 May 4
Selective antibodies to methadone enantiomers: synthesis of (R)- and (R,S)-methadone conjugates and determination by an immunoenzymatic method in human serum.
2001 May 5
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations.
2001 May-Jun
Scalp nerve blocks decrease the severity of pain after craniotomy.
2001 Nov
The role of adrenal corticosteroids in induction of micronuclei by morphine.
2001 Nov 15
Nutritional effects of surgical and medical treatment for short bowel syndrome.
2001 Nov-Dec
Novel dynamic polymer coating for capillary electrophoresis in nonaqueous methanolic background electrolytes.
2001 Oct
Seizures with intravenous codeine phosphate.
2001 Oct
Incorporation of selegiline metabolites into hair after oral selegiline intake.
2001 Oct
Ropivacaine with or without clonidine improves pediatric tonsillectomy pain.
2001 Oct
Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients.
2001 Oct 1
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.
2001 Sep
Community pharmacists' experience of over-the-counter medicine misuse in Scotland.
2001 Sep
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial.
2001 Sep
Detection of non-prescription heroin markers in urine with liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.
2001 Sep
Patents

Patents

05869669
14
08337890
16
08710069
12
08790700
16
JP2002104963A
12
JP2002511777A
420
JP2006520379A
75
JP2009520033A
20
JP2011507842A
17
JP4804361B2
32
JPH00286794A
24
JPS5323998A
14
JPS572288A
16

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:48:29 GMT 2025
Edited
by admin
on Mon Mar 31 17:48:29 GMT 2025
Record UNII
GSL05Y1MN6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CODEINE PHOSPHATE HEMIHYDRATE
EP   WHO-DD   WHO-IP  
Preferred Name English
CODEINE PHOSPHATE
ORANGE BOOK   USP   VANDF   WHO-IP  
Common Name English
CODEINE PHOSPHATE CII
USP-RS  
Common Name English
DIMETANE-DC COMPONENT CODEINE PHOSPHATE
Common Name English
CODEINE PHOSPHATE [VANDF]
Common Name English
CODEINE PHOSPHATE [ORANGE BOOK]
Common Name English
CODEINE PHOSPHATE HYDRATE [JAN]
Common Name English
CODEINE PHOSPHATE CII [USP-RS]
Common Name English
7,8-Didehydro-4,5?-epoxy-3-methoxy-17-methylmorphinan-6?-ol phosphate (1:1) (salt) hemihydrate
Common Name English
CODEINE PHOSPHATE HEMIHYDRATE [EP MONOGRAPH]
Common Name English
AMBENYL COMPONENT CODEINE PHOSPHATE
Common Name English
CODEINE PHOSPHATE [WHO-IP]
Common Name English
TRIACIN-C COMPONENT CODEINE PHOSPHATE
Common Name English
CODEINI PHOSPHAS [WHO-IP LATIN]
Common Name English
MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-, (5.ALPHA.,6.ALPHA.)-, PHOSPHATE (SALT), HYDRATE (2:2:1)
Common Name English
COLREX COMPOUND
Brand Name English
BROMANYL COMPONENT CODEINE PHOSPHATE
Common Name English
MYPHETANE DC COMPONENT CODEINE PHOSPHATE
Common Name English
AMBENYL COUGH SYRUP
Brand Name English
CODEINE PHOSPHATE BP
Common Name English
CODRIX COMPONENT CODEINE PHOSPHATE
Common Name English
MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-, (5.ALPHA.,6.ALPHA.)-, PHOSPHATE (1:1) (SALT), HEMIHYDRATE
Common Name English
CODEINE PHOSPHATE [USP MONOGRAPH]
Common Name English
BROMANATE DC COMPONENT CODEINE PHOSPHATE
Common Name English
Codeine phosphate hemihydrate [WHO-DD]
Common Name English
CODEINE PHOSPHATE HEMIHYDRATE [WHO-IP]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 1308.15
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
CFR 21 CFR 290.2
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
NCI_THESAURUS C1657
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
DEA NO. 9050
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
CFR 21 CFR 341.14
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
CFR 21 CFR 341.74
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
Code System Code Type Description
EVMPD
SUB29134
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
EPA CompTox
DTXSID20904612
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
DRUG BANK
DBSALT000030
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
SMS_ID
100000090188
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
PUBCHEM
6321303
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
NCI_THESAURUS
C74548
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
RS_ITEM_NUM
1144000
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
CAS
41444-62-6
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
ChEMBL
CHEMBL485
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
RXCUI
2672
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
CODEINE PHOSPHATE
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY Description: Small, colourless crystals or a white, crystalline powder; odourless.Solubility: Soluble in 4 parts of water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R.Category: Antitussive; analgesic.Storage: Codeine phosphate should be kept in a tightly closed container, protected from light.Labelling: The designation on the container should state if the Codeine phosphate is the hemihydrate or the sesquihydrate.Additional information. Codeine phosphate effloresces in dry air.
DAILYMED
GSL05Y1MN6
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
FDA UNII
GSL05Y1MN6
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
EVMPD
SUB13428MIG
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
EVMPD
SUB13427MIG
Created by admin on Mon Mar 31 17:48:29 GMT 2025 , Edited by admin on Mon Mar 31 17:48:29 GMT 2025
PRIMARY
Related Record Type Details
Structure of CODEINE ANHYDROUS
PARENT -> SALT/SOLVATE
Structure of CODEINE PHOSPHATE ANHYDROUS
ANHYDROUS->SOLVATE
Structure of CODEINE PHOSPHATE SESQUIHYDRATE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of ORIPAVINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of NORCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 7,7-OXYBIS(4,5.ALPHA.-EPOXY-3-METHOXY-17-METHYL-6,7,8,14-TETRADEHYDROMORPHINAN-6-OL)
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Thebaine
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 14-HYDROXYCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 10-HYDROXYCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYLCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-O-(CODEIN-2-YL)MORPHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CODEINONE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of MORPHINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Hydroxycodeinone
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CODEINE N-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,2'-BISCODEINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of CODEINE ANHYDROUS
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966